Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y3KG
|
||||
| Former ID |
DCL001031
|
||||
| Drug Name |
Valproate
|
||||
| Synonyms |
Avugane; Baceca; Convulex; Convulsofin; Depakene; Depakin; Depakine; Deproic; Dipropylacetate; Ergenyl; Mylproin; Savicol; Stavzor; VPA; Valproinsaeure; Vupral; Acide valproique; Acido valproico; Acidum valproicum; Depakin chrono; Depakine chrono; Dipropyl Acetate; Dipropylacetic acid; Med Valproic; Myproic Acid; Propylvaleric acid; Semisodium Valproate; VALPROIC ACID; Valproic acid USP; Abbott 44090; Valproic acid USP24; Acide valproique [INN-French]; Acido valproico [INN-Spanish]; Acidum valproicum [INN-Latin]; Alti-Valproic; Depakene (TN); Depakote (TM); Dom-Valproic; G2M-777; Kyselina 2-propylvalerova; Kyselina 2-propylvalerova [Czech]; N-DPA; N-Dipropylacetic acid; Novo-Valproic; Nu-Valproic; PMS-Valproic Acid; Penta-Valproic; Valproic acid (USP); Di-n-propylacetic acid; Di-n-propylessigsaeure; Di-n-propylessigsaure; Di-n-propylessigsaure [German]; Valproic acid [USAN:INN:BAN]; Valproic Acid, SodiumSalt (2:1); 2 PP (base); 2-Propylpentanoic acid; 2-Propylvaleric acid; 2-n-Propyl-n-valeric acid; 4-Heptanecarboxylic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Epilepsy [ICD10:G40] | Approved | [1] | ||
| Alcohol use disorders [ICD9: 303; ICD10:F10.2] | Phase 2 | [2] | |||
| Therapeutic Class |
Neurology Agents
|
||||
| Company |
Abbot Phamaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C8H16O2
|
||||
| Canonical SMILES |
CCCC(CCC)C(=O)O
|
||||
| InChI |
1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
|
||||
| InChIKey |
NIJJYAXOARWZEE-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 76584-70-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9394, 399407, 621684, 3138784, 4918409, 7847465, 7980632, 8151988, 10539166, 11335448, 11360687, 11363415, 11364691, 11365977, 11367253, 11368539, 11369815, 11372725, 11372856, 11374010, 11375415, 11376701, 11377978, 11461659, 11484648, 11488762, 11491548, 11492191, 11494335, 12015354, 14710660, 15321539, 17389523, 24898751, 26697333, 26752920, 26752921, 29222263, 46260925, 46505925, 48416692, 48424277, 48425730, 49635685, 49640649, 49856166, 50062089, 50105536, 53788878, 56310655
|
||||
| SuperDrug ATC ID |
N03AG01
|
||||
| SuperDrug CAS ID |
cas=000099661
|
||||
| Target and Pathway | |||||
| Target(s) | Glycogen synthase kinase-3 | Target Info | Inhibitor | [3], [2] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Insulin/IGF pathway-protein kinase B signaling cascade | |||||
| PDGF signaling pathway | |||||
| Ras Pathway | |||||
| Pathway Interaction Database | Degradation of beta catenin | ||||
| Canonical Wnt signaling pathway | |||||
| FOXM1 transcription factor network | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| Reactome | AKT phosphorylates targets in the cytosol | ||||
| XBP1(S) activates chaperone genes | |||||
| Constitutive Signaling by AKT1 E17K in Cancer | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76. | ||||
| REF 3 | Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.